Multiple Sclerosis Clinical Trials in Phoenix

Showing 381-400 of 574 trials

TARGET Intracranial Aneurysm Coiling Registry

NCT01748903

The purpose of this prospective registry is to collect real world, post-marketing data on the use of Stryker Target® 360,Target® 2D, and 2nd generation Target® Nano coils for the embolization of ruptured or unruptured intracranial saccular aneurysms. Up to 300 patients (150 in the TARGET 360°/Helical arm and 150 in the New NANO arm) presenting with intracranial aneurysms suitable for coil embolization will be enrolled at up to 20 sites. A post hoc analysis comparing Target® 360° and Target® 2D coil technical and clinical endpoints will be performed.

Intracranial Aneurysms

Mercy Health Ohio150 participantsStarted Feb 2013

Phoenix, Arizona, United States • Tallahassee, Florida, United States • Joliet, Illinois, United States +6 more locations

COMPLETEDPhase 4< 1 mile

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338

The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.

Relapsing-remitting Multiple Sclerosis

EMD Serono764 participantsStarted Feb 2004

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +77 more locations

TARGET Intracranial Aneurysm Coiling Registry

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis Trials in Other Cities

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

TR(ACE) Assay Clinical Specimen Study

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Other Conditions in Phoenix